On February 13, 2024, Eric Benevich, Chief Commercial Officer of Neurocrine Biosciences Inc (NBIX, Financial), executed a sale of 1,098 shares of the company. The transaction was filed with the SEC and can be found through this SEC Filing.
Neurocrine Biosciences Inc is a biopharmaceutical company focused on developing treatments for neurological and endocrine-related diseases and disorders. The company's portfolio includes products and product candidates for a range of medical conditions, aiming to address unmet medical needs and improve patient care.
Over the past year, the insider has sold a total of 6,165 shares and has not made any purchases of the company's stock. The recent sale by the insider is part of a broader trend observed over the past year, where there have been no insider buys and 63 insider sells for Neurocrine Biosciences Inc.
On the date of the insider's recent sale, shares of Neurocrine Biosciences Inc were trading at $133.01, giving the company a market capitalization of $13.337 billion. The price-earnings ratio stood at 55.37, above the industry median of 22.37 but below the company's historical median price-earnings ratio.
According to the GF Value, with a share price of $133.01 and a GuruFocus Value of $148.93, Neurocrine Biosciences Inc's price-to-GF-Value ratio is 0.89, indicating that the stock is modestly undervalued.
The GF Value is calculated based on historical trading multiples, a GuruFocus adjustment factor related to the company's past performance, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
